Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research focused on Capecitabine and Epirubicin, with related work in Oncology, Triple-negative breast cancer, Docetaxel. Notable publications include 'Challenges to effective cancer control in China, India, and Russia', 'Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial', and 'A retrospective analysis of serum tumor markers found in non-small cell lung cancer'.
Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial
Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis
Exploration of Specific Population for Adjuvant Capecitabine Escalation Therapy in Early-Stage Triple-Negative Breast Cancer: A Retrospective Biological Sample Analysis of the CBCSG010 Clinical Trial
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial
A retrospective analysis of serum tumor markers found in non-small cell lung cancer
Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer.
Challenges to effective cancer control in China, India, and Russia